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Editorial on the Research Topic
Autoinflammatory Diseases: From Genes to Bedside
The year 2019 marked the 20th anniversary of the formal recognition of autoinflammatory diseases
as a distinct group of rheumatological conditions, following the identification of the gene mutated
in patients with a dominantly inherited periodic fever known as familial Hibernian fever (FHF) (1).
This nosological concept was introduced by one of the founders of the field, Dr. Daniel Kastner.
Prior to this time, the only recognized periodic fever disease was familial Mediterranean fever
(FMF) and patients presenting with similar symptoms, irrespective of inheritance pattern, were
suspected to have a variant FMF. Most patients, with exception for FMF, were treated with NSAID,
glucocorticoids alone, or in a combination with immunosuppressive agents. These chronic life-
long conditions negatively impacted patients’ quality of life and were associated with significant
morbidity and mortality, partially due to treatment-related side effects.
The early advances in the field of autoinflammation were driven by the ascertainment of
families with inflammatory phenotypes segregating either as a recessive (FMF) or dominantly
(FHF) inherited trait. This allowed for linkage mapping, positional cloning and candidate gene
screening even before the completion of human genome sequencing project in 2003. These
gene-hunting projects were laborious and time-consuming, but nonetheless successful and led to
identification of the first three genes associated with autoinflammatory diseases:MEFV, TNFRSF1A,
and CIAS1/NLRP3.
Familial Mediterranean fever was the first disease to be characterized at the molecular level.
FMF, being a common illness in multiple Mediterranean populations, was initially noted in the
literature by Galen in the second century AD. Although there were reports of cases with cyclic
fevers and pains in the nineteenth century, it remained a mysterious disease and its pathogenesis
was attributed to the phases of the moon and other environmental factors. Genetic etiology was not
suspected until 1958 whenDr. HarryHeller emphasized the genetic nature of the disease and coined
itsmodern name familialMediterranean fever (2). The first accurate clinical description of FMFwas
published in 1945 by Dr. Sheppard Siegal, who reported 10 patients suffering from recurrent bouts
of abdominal pain and fevers but who between attacks “may enjoy good health” (3). He named the
disease “benign paroxysmal peritonitis.” The next major break-through was in the early nineties,
when Drs. Daniel Kastner and Isabelle Touitou undertook finding the causal gene for FMF (4, 5).
Independently, they collected many families with FMF to launch genome-wide linkage mapping.
This was incredibly ambitious considering available techniques, Southern blot analysis of DNA by
restriction fragment length polymorphism (RLFP) markers not dense enough to cover the entire
human genome. Complete sequences of many expressed genes were not available. After 7 years
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of tedious labor, a poorly characterized transcript harboring
bi-allelic missense pathogenic mutations associated with FMF
was identified. This discovery was celebrated at the First
International Meeting on FMF in the summer of 1997 at
Jerusalem, which was organized by Dr. Mordechai Pras.
It was not until late nineties that the second periodic
fever disease came to attention. Although a five-generation
family of the European ancestry with dominantly inherited
fevers was described in 1957 by Drs. Bouroncle and Doan (6),
most physicians were not aware of the disease. In 1998, the
molecular basis of familial Hibernian fever was elucidated with
the identification of heterozygous mutations in the TNFRSF1A
gene (1). The disease was renamed tumor necrosis factor (TNF)
receptor-1 associated periodic syndrome (TRAPS) and the term
autoinflammation was coined to describe new diseases of the
innate immune system (1).
A new era of medical and genetic research in
autoinflammation had begun. In 2002, Drs. Hoffman and
Kolodner identified heterozygous mutations in the CIAS1 gene
in patients with dominantly inherited cold urticaria (FCAS)
and Muckle-Wells (MWS) syndromes, both diseases considered
cryopyrin-associated periodic syndromes (CAPS) (7). Another
remarkable discovery from this study was that pyrin (encoded
by MEFV) and the NLRP3 protein share the same N-terminal
∼92aa domain denoted as pyrin domain (PYD). This finding
suggested the existence of common pathways in the pathogenesis
of autoinflammation. Subsequently, a whole family of proteins
with the pyrin domain was identified by in silico analysis. Many
of these proteins function as intracellular sensing receptors
to recognize foreign or self-generated danger-associated
molecular patterns. They form a molecular complex known as
inflammasome that was discovered and characterized in 2002
by the team of late Dr. Jurg Tschopp (8). The initial observation
that gain-of-function mutations in the NLRP3 inflammasome
lead to increased production of IL-1β formed the basis for
genomically-informed therapies. Over time, numerous studies in
human cells and murine models showed that IL-1β plays a major
role in the pathogenesis of autoinflammatory diseases. These
three discoveries established the basis for an entirely new field
of investigation.
The next chapter began around 10 years ago with the
development of new genomic technologies, next-gene
sequencing (NGS), bioinformatics, and the completion of
human genome project. These strategies provided researchers
and clinicians a variety of tools for gene-hunting projects.
Genetic discoveries are now often made in a matter of months
if not weeks. The list of genes associated with monogenic
autoinflammatory diseases has grown rapidly and currently
includes more than 30 genes. Advanced sequencing technologies
revealed unusual inheritance patterns including somatic
mutations as the cause of adult-onset diseases and cases with
digenic inheritance. Digenic inheritance refers to presence
of pathogenic mutations in two interacting proteins as the
cause of a disease. High-throughput sequencing has brought to
light a number of variants with uncertain clinical significance
(VUS). Attempts to clarify the clinical implication of these
low frequency (1–5%) variants have been carried out through
international collaborations. Despite of major accomplishments
in dissecting the genetic basis of autoinflammatory conditions,
the genetic cause of disease for many patients remains unknown.
To complicate things, many of these patients are sporadic cases
and it may require orchestrated efforts between multiple research
groups to find causal genes.
The field of molecular diagnostics for autoinflammatory
diseases has seen substantial growth, providing physicians
with the specific information necessary to diagnose and treat
patients. There are close to 100 academic and commercial
laboratories across the world that perform genetic by testing
through single-gene or targeted gene panel analysis, or
whole exome sequencing. An international group of experts
has been convened in effort to standardize genetic reports
and develop consensus guidelines for interpretation of
genetic variants.
We have learned a great deal about a wide spectrum of
clinical manifestations in patients with autoinflammation. It
is likely, as is the case with most human traits, that these
phenotypic differences will be explained by modifying gene
alleles, epigenetics effects, and environmental factors. Deficiency
of adenosine deaminase 2 (DADA2) is case in point: patients
may present with fevers, rash, ischemic strokes or with a
sole manifestation of pure red cell aplasia. Mutations in the
same protein—often in different domains—may give rise to
distinct clinical features, therefore these phenotypes need to
be referred to in the context of mutant protein e.g., Pyrin-,
NOD2-, NLRP3-, or NLRC4-associated diseases. In contrast, a
distinct phenotype, such is the case with cold-induced urticaria,
could be caused by pathogenic mutations in different genes
(NLRP3, NLRC4, NLRP12, PLCG2, FXII). About a decade
ago an immunological continuum was proposed to designate
patients who present with features of autoinflammation and
autoimmunity (9). Recent studies described patients with cell-
specific features of autoinflammation and/or immunodeficiency.
Studies of molecular pathways in murine models have shed
light on broad aspects of the biology of inflammatory responses.
Mice deficient for inflammasome components have become
instrumental in dissecting signaling pathways that regulate
innate immune responses. Studies utilizing pyrin knock-out
mice, showed that the pyrin inflammasome has evolved as an
innate immune sensor to detect bacterial-induced modifications,
which is the first known example of the “guard mechanism” in
mammalian innate immunity (10).
A number of “biologicals” have been developed to treat
acute inflammation in patients with a broad spectrum of
systemic inflammatory diseases. Targeted cytokine therapies,
in particular anti-IL1 and anti-TNF, have been efficacious
and with minimal side effects in treating patients with
autoinflammation even without a known molecular cause
of disease. Non-biological drugs such as JAK-STAT inhibitors
have recently emerged and are promising in treating patients
with interferon-mediated disorders including CANDLE
(Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy
and Elevated Temperature) syndrome, STING-associated
vasculopathy with onset in infancy (SAVI) and Aicardi-Goutieres
syndrome (AGS).
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The term autoinflammation has spread beyond the
boundaries of internal medicine and rheumatology, and
is now used in disciplines of dermatology, immunology,
and neurology. Dysregulation of the innate immune
system is increasingly considered to have role in the
pathogenesis of many human conditions, including common
multifactorial cardiovascular, metabolic, neurodegenerative,
autoimmune diseases, and in particular in polygenic or
systemic inflammatory diseases, such as Behçet disease and
periodic fever, aphthous stomatitis, pharyngitis and cervical
adenitis (PFAPA) syndrome. A better understanding of the
molecular mechanisms underlying dysregulation of the innate
immune system will provide a foundation for developing
more affordable and effective treatments. Witnessing these
developments has been incredibly rewarding for those of
us in the field and it will be exciting to see where it goes
from here.
In the present issue of Frontiers in Immunology,
“Autoinflammatory diseases: from genes to bedside,” the
first monographic issue about autoinflammatory diseases, several
investigators have contributed with original and review articles
covering genetic, pathogenic, epigenetic, clinical and therapeutic
aspects of different autoinflammatory conditions.
The “genes” part of the topic explores relevant genetic,
pathogenic and epigenetic mechanisms implicated in
autoinflammatory diseases. Martorana et al.. review the most
common mutations and the evidences of genotype/phenotype
correlations of the main monogenic autoinflammatory diseases.
The role of NLRP3 and pyrin inflammasomes in the pathogenesis
of CAPS, and FMF and pyrin-associated autoinflammation with
neutrophilic dermatosis (PAAND), respectively, has been
addressed by de Torre-Minguela et al.. Aksentijevich and Zhou
describe the latest advances on the pathogenic mechanisms of
ubiquitinopathies, a new category of autoinflammatory diseases
involved in the NF-κB pathway, which include linear ubiquitin
chain assembly complex (LUBAC) and OTULIN deficiencies,
and haploinsufficiency of A20. Carta et al.. propose two
different pathways of inducing abnormal IL-1β production in
autoinflammatory diseases depending on the cell type affected, in
which the authors postulate that professional inflammatory cells
would cause a direct inflammatory response and non-immune
cells may participate indirectly in the inflammatory cascade by
releasing stress signals that trigger and propagate inflammation.
In the same sense, Gül reviews the concept of autoinflammation
and uses it for monogenic and polygenic autoinflammatory
diseases associated with seemingly unprovoked inflammatory
episodes mediated mainly by the innate immune system. In
addition, Gül also proposes and expands nomenclature by
using the concept of “hyperinflammatory” state for those
disorders characterized by episodes of exaggerated inflammatory
response only when triggered by certain factors or situations.
Álvarez-Errico et al.. review the recent advances on the
contribution of epigenetic mechanisms in the disease expression
of some autoinflammatory diseases.
The “bedside” part of the topic reviews important clinical
and translational research, and therapeutic contributions in
autoinflammatory diseases. Özen et al.. wrote a comprehensive
overview about what are still considered unsolved problems
in FMF, such as the involved mechanism of the disease,
inheritance patterns and treatment in colchicine resistant
patients. Ruiz-Ortiz et al.. make an original contribution in
characterizing clinical manifestations associated with the low-
penetrance R92Q variant in TNFRSF1A and differentiating
disease phenotypes between patients with pediatric and adult
onset. In an article about CANDLE syndrome, Torrelo et
al. reviews in depth all the pathophysiological, clinical, and
biologic features of this complex monogenic interferonopathy.
The cytokine signature in patients with Behçet disease is
explored by Lopalco et al., who suggest an increased signature
of IL-6, TNF-α, and Th17 in patients with mucocutaneous
and uveitis manifestations. Cantarini et al.. propose a set of
clinical diagnostic criteria for adult-onset PFAPA syndrome
with a high-predictive potential for identifying PFAPA patients
among subjects with fever of unknown origin. Finally, in
two review articles, Figueras-Nart et al.. analyze the most
remarkable dermatologic and dermatopathologic features of
monogenic autoinflammatory diseases by using a classification
based on the predominant cutaneous lesion, and Soriano et al.
describe the current treatment of the most frequent monogenic
autoinflammatory diseases and PFAPA syndrome based on the
best available evidence and also propose a practical guide to
their management.
This first monography entirely dedicated to autoinflammatory
diseases provides stimulating information on many of the past,
present and future advances and challenges in this field.
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